- Home
- AIRJ vs CMPX Comparison
AIRJ vs CMPX Comparison
Compare AIRJ & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRJ
- CMPX
- Stock Information
- Founded
- AIRJ N/A
- CMPX 2014
- Country
- AIRJ United States
- CMPX United States
- Employees
- AIRJ N/A
- CMPX N/A
- Industry
- AIRJ
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- AIRJ
- CMPX Health Care
- Exchange
- AIRJ NYSE
- CMPX Nasdaq
- Market Cap
- AIRJ 272.7M
- CMPX 229.5M
- IPO Year
- AIRJ N/A
- CMPX N/A
- Fundamental
- Price
- AIRJ $4.99
- CMPX $1.75
- Analyst Decision
- AIRJ Strong Buy
- CMPX Strong Buy
- Analyst Count
- AIRJ 1
- CMPX 8
- Target Price
- AIRJ $12.00
- CMPX $13.38
- AVG Volume (30 Days)
- AIRJ 99.5K
- CMPX 2.8M
- Earning Date
- AIRJ 05-26-2025
- CMPX 05-12-2025
- Dividend Yield
- AIRJ N/A
- CMPX N/A
- EPS Growth
- AIRJ N/A
- CMPX N/A
- EPS
- AIRJ 4.03
- CMPX N/A
- Revenue
- AIRJ N/A
- CMPX $850,000.00
- Revenue This Year
- AIRJ N/A
- CMPX $47.65
- Revenue Next Year
- AIRJ N/A
- CMPX $2,767.57
- P/E Ratio
- AIRJ $1.23
- CMPX N/A
- Revenue Growth
- AIRJ N/A
- CMPX N/A
- 52 Week Low
- AIRJ $4.25
- CMPX $0.77
- 52 Week High
- AIRJ $21.78
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- AIRJ 36.50
- CMPX 41.42
- Support Level
- AIRJ $4.75
- CMPX $1.60
- Resistance Level
- AIRJ $5.27
- CMPX $1.78
- Average True Range (ATR)
- AIRJ 0.52
- CMPX 0.27
- MACD
- AIRJ 0.07
- CMPX 0.03
- Stochastic Oscillator
- AIRJ 59.68
- CMPX 38.01
About AIRJ MONTANA TECHNOLOGIES CORP
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.